

AF1653

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q62621

Satoshi SASAKI, et al.

Appln. No.: 09/744,328

Group Art Unit: 1653

Confirmation No.: 4446

Examiner: Chih Min Kam

Filed: January 23, 2001

For: PHARMACEUTICAL COMPOSITION HAVING INHIBITORY EFFECT ON
OVERPRODUCTION AND ACCUMULATION OF EXTRACELLULAR MATRIX

STATEMENT OF SUBSTANCE OF INTERVIEW

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Please review and enter the following remarks summarizing the interview conducted on
March 30, 2004:

REMARKS

An Examiner's Interview Summary Record (PTO-413) given personally to the
undersigned at the conclusion of the interview on March 30, 2004.

During the interview, the following was discussed:

1. Brief description of exhibits or demonstration: None.
2. Identification of claims discussed: Claims 1 and 25.

Statement of Substance of Interview
U.S. Serial No.: 09/744,328


3. Identification of art discussed: None.
4. Identification of principal proposed amendments: The examiners proposed amending claims 1 and 25 to identify the compound that inhibits the biological activity of galectin-3 as a compound that inhibits the binding of galectin-3 to sugars.
5. Brief Identification of principal arguments: The undersigned argued that the amendment filed by January 30, 2004, should have been entered because, contrary to the examiners' position, amending claim 25 to recite a method of therapeutic or preventive treatment in place of a method for inhibition of various diseases, does not raise a new issue of patentability. The undersigned asserted that a method for inhibition of a disease would include preventative treatment.
6. Indication of other pertinent matters discussed: The examiners and the undersigned discussed the types of compounds that inhibit the biological activity of galectin-3 in the pharmaceutical composition and in the method of treatment. The examiners and the undersigned also discussed extrapolating *in vitro* data to *in vivo* effect.
7. Results of Interview: No agreement was reached.

It is believed that no petition or fee is required. However, if the USPTO deems otherwise, Applicant hereby petitions for any extension of time which may be required to

Statement of Substance of Interview
U.S. Serial No.: 09/744,328

maintain the pendency of this case, and any required fee, except for the Issue Fee, for such extension is to be charged to Deposit Account No. 19-4880.

Respectfully submitted,



Susan J. Mack
Registration No. 30,951

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: April 30, 2004